Zetomipzomib, A Selective Inhibitor of the Immunoproteasome: Preclinical & Clinical Activity in Lupus Nephritis
Time: 4:00 pm
day: Conference Day One
Details:
- Demonstrating activity of zetomipzomib in a mouse model of lupus nephritis and impact on lupus gene signature pathways
- Summarising clinical data from lupus nephritis patients in Mission study
- Providing overview of ongoing PALIZADE clinical trial: a Phase 2b placebo-controlled study in lupus nephritis patients
